Sexual Health & Hormonal Research High Evidence

PT-141 (Bremelanotide)

Melanocortin receptor agonist (MC4R) studied for sexual dysfunction in both males and females. FDA-approved for HSDD in premenopausal women (Vyleesi).

sexual dysfunctionHSDDmelanocortinarousalFDAbremelanotide

Ask AI About This Compare Compounds

Half-life

120 minutes

SKUs

Evidence

High Evidence

📖 What Is This?

PT-141 is the research name for bremelanotide — the same compound that became FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. In research contexts it is sometimes referred to as PT-141. It activates melanocortin receptors in the brain to increase sexual desire through central nervous system pathways rather than through direct vascular effects.

🔬 What Are Researchers Studying It For?

Female Sexual Desire Disorder

PT-141 (bremelanotide) was studied in the RECONNECT phase 3 trials in premenopausal women with HSDD. The trials showed statistically significant increases in satisfying sexual events and decreases in desire-related distress compared to placebo. FDA approval was granted in 2019 under the name Vyleesi.

Male Sexual Dysfunction

Early development of PT-141 examined it for erectile dysfunction in men. Research demonstrated pro-erectile effects, though development for male indications did not advance to approval. The compound produces central arousal and can cause erections in men through brain rather than vascular mechanisms.

Melanocortin System Research

PT-141 research has contributed to broader understanding of how the melanocortin system in the brain regulates sexual motivation. The identification that MC4R activation increases sexual desire has influenced subsequent drug development in this area.

📊 What Does The Research Suggest?

FDA-approved for HSDD in premenopausal women as Vyleesi.
Phase 3 trials showed increased satisfying sexual events and reduced distress vs placebo.
Pro-erectile effects demonstrated in men in early trials.
Centrally-acting through melanocortin receptors — mechanism differs from PDE5 inhibitors.
Transient blood pressure increase is a documented pharmacological effect.

⚠️ What Should You Know Before Going Deeper?

PT-141/bremelanotide is FDA-approved only for premenopausal women with HSDD — not for postmenopausal women, men, or for general sexual enhancement. It causes a transient blood pressure increase after dosing, which limits its use in people with cardiovascular risk. Nausea affects a significant proportion of users. It is taken before anticipated activity, not as a daily medication.

⚙️ How It Works In The Body

Sexual desire originates in the brain, not just in the body. PT-141 works by activating melanocortin-4 receptors (MC4R) in brain regions involved in motivation and desire. These receptors, when activated, turn up activity in circuits that generate sexual interest. This is different from how drugs like Viagra work — those act on blood vessels to increase physical arousal. PT-141 acts upstream on the motivational desire pathways themselves. The result is that it can increase the subjective experience of wanting sexual activity through a brain mechanism, rather than simply facilitating the physical response once desire already exists.

🛡️ Research Safety Observations

FDA-approved as Vyleesi with an established safety profile. The most important safety consideration is a transient increase in blood pressure that occurs after dosing and lasts several hours — this limits its use in people with cardiovascular conditions. Nausea is common, particularly at higher doses. It should not be used more than once in 24 hours. The blood pressure increase is a class-level effect of MC4R activation and was observed consistently across trials.

📋 Research Snapshot

High Evidence

This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.

Published Research Ranges

1.25–1.75mg SC in FDA-approved study ranges

Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

📄 Research Sources

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction

Annals of the New York Academy of Sciences • 2003 • DOI: 10.1111/j.1749-6632.2003.tb07127.x

PT-141 (Bremelanotide)

Want More Detailed Research?